3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
9
Unknown
7
Completed
6
Not yet recruiting
4
Active not recruiting
4
Withdrawn
1
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
5
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
9
Paclitaxel
9
Doxorubicin
6
Cyclophosphamide
6
Carboplatin
5
130-nm albumin-bound paclitaxel
5
durvalumab
3
yeast-CEA vaccine
2
talazoparib
2
sacituzumab govitecan
2
olaparib
2
glembatumumab vedotin
2
avelumab
2
Taxes
2
Radiotherapy
2
Leucovorin
2
Fluorouracil
2
Cisplatin
2
Capecitabine
2
Biopsy
2
Albumin-Bound Paclitaxel
2
ALT-803
2
zimberelimab
1
trifluridine tipiracil drug combination
1
tremelimumab
1
trastuzumab duocarmazine
1
tislelizumab
1
taxane
1
sabizabulin
1
poly ICLC
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Triple Negative Breast Neoplasms
×
Epirubicin
×
Clear all
NCT06829199
2026-02-19
MK-5890-003
Merck Sharp & Dohme LLC
Phase 2
Withdrawn